Drug intelligence / Profile preview

PSMA-81

Development stage
Preclinical
Lead developer
Corellia AI
Modality
Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

PSMA-81 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Corellia AI for the treatment of prostate cancer. Utilizing Corellia's proprietary Coromip technology, PSMA-81 features a dual-targeting mechanism that binds to both prostate-specific membrane antigen (PSMA) and CD180 on the surface of cancer cells. This specific targeting allows for the selective delivery of its cytotoxic payload, the PI3K/mTOR inhibitor omipalisib (also known as compound '81'), directly into the tumor microenvironment. By combining the precision of antibody-mediated delivery with the potent kinase inhibition of omipalisib, PSMA-81 is designed to maximize therapeutic efficacy while reducing systemic toxicity. The drug is currently in the discovery and in vivo stages of preclinical development.

Other names
Coromip

Beyond the preview

Go deeper on PSMA-81.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSMA-81.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call